EUCTR2008-000972-25-ES进行中（未招募）1 期
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase 3 study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap.
AB Science0 个研究点目标入组 150 人开始时间: 2014年10月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patient with one of the following documented mastocytosis as per WHO classification:
- •Smouldering Systemic Mastocytosis
- •Indolent Systemic Mastocytosis
- •2. Patient with documented mastocytosis and evaluable disease based upon histological criteria: typical
- •infiltrates of mast cells in a multifocal or diffuse pattern in skin and/or bone marrow biopsy
- •3. Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy
- •used at optimized dose (refer to table 2):
- •Proton pump inhibitor
- •Osteoclast inhibitor
- •Cromoglycate Sodium
- •Antileukotriene
- •4. Handicapped status defined as at least two of the following handicaps, including at least one among pruritus,
- •flushes, depression and fatigue:
- •Pruritus score ? 9
- •Number of flushes per week ? 8
- •Hamilton rating scale for depression(HAMD-17) score ? 19
- •Number of stools per day ? 4
- •Number of micturition per day ? 8
- •Fatigue Impact Scale total score (asthenia) ? 75
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Patient with one of the following mastocytosis:
- •?Cutaneous Mastocytosis
- •?Not documented Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis
- •?Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD)
- •?Mast cell leukaemia (MCL)
- •?Aggressive systemic mastocytosis (ASM)
- •2.Previous treatment with any Tyrosine Kinase Inhibitor
- •3.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •?Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •?Patient with cardiac failure class III or IV of the NYHA classification
- •?Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •?Syncope without known aetiology within 3 months
- •?Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •4.Patient who had major surgery within 2 weeks prior to screening visit
- •5.Vulnerable population defined as:
- •?Life expectancy < 6 months
- •?Patient with < 5 years free of malignancy, except treated basal cell skin cancer or cervical carcinoma in situ
- •?Patient with any severe and/or uncontrolled medical condition
- •?Patient with known diagnosis of human immunodeficiency virus (HIV) infection
- •6.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent, or institutionalized by court decision
- •7.Patient with any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events
- •Previous treatment
- •8.Change in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within 4 weeks prior to baseline
- •9.Treatment with any investigational agent within 4 weeks prior to baseline
研究者
相似试验
进行中（未招募）
1 期
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapSmouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapsMedDRA version: 9.1 Level: LLT Classification code 10026891 Term: MastocytosisEUCTR2008-000972-25-FRAB SCIENCE200
进行中（未招募）
1 期
A 24-week with possible extension study to compare efficacy and safety of masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosisSmouldering or Indolent Severe Systemic mastocytosisEUCTR2016-001447-39-FRAB SCIENCE140
进行中（未招募）
1 期
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapSmouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicapsMedDRA version: 9.1Level: LLTClassification code 10026891Term: MastocytosisEUCTR2008-000972-25-BGAB SCIENCE223
进行中（未招募）
1 期
Study to compare efficacy and safety of masitinib at 6 mg/kg/day toplacebo in treatment of patients with Systemic mastocytosis with severe handicapSmouldering Systemic or Indolent Systemic Mastocytosis with handicap.MedDRA version: 17.0Level: PTClassification code 10026891Term: MastocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2008-000972-25-GRAB Science150
Unknown
2 期
multicenter, randomized, double-blind, controlled, Phase 2b/3 study to compare efficacy and safety of AB1010 at 3 and 6 mg/kg/day in treatment of patients which active rheumatoid arthritisCTRI/2014/09/005044AB SCIENCE450